Thursday, December 01, 2016 10:43:12 PM
...One possible path from Antigen Express to Peregrine... may be via Dr. George Peoples, one of the listed contributors here:
Sonia A. Perez PhD 1,
Eric von Hofe PhD 2,
Nikoletta L. Kallinteris MSCE 2,
Angelos D. Gritzapis PhD 1,
George E. Peoples MD 3,
Michael Papamichail MD, PhD 1,
Constantin N. Baxevanis PhD 1,
1 Cancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece
2 Antigen Express Inc., Biotec III, Worcester, Massachusetts
3 Department of Surgery, General Surgery Service, Brooke Army Medical Center, Fort Sam Houston, Texas
http://onlinelibrary.wiley.com/doi/10.1002/cncr.24988/abstract
----------------------------------------------------------------
Digging deeper.... how does one go from Worcester to Tustin? Now if you search enough you see "MANY" correlations here but I'll list one only because I'm sure you don't want to be reading much longer:
MD Anderson Cancer Center researcher Dr. Elizabeth A Mittendorf is the principal investigator and George E. Peoples from Brooke Army Medical Center is the Study Director of trial that is being funded and collaborated by San Antonio Military Medical Center, Norwell, Inc and Antigen Express, Inc.
http://bionews-tx.com/news/2013/10/07/us-military-opens-clinical-trials-for-breast-cancer-vaccine-internationally/
Things begin to get a little more exciting for those with valid biomarkers.... and a little bit more frustrating for those that do not have valid biomarkers. I picked up another puzzle piece and 100% tied here---- so I'd say Peregrine was in the midst of picking out the top 6 biomarkers and if you listen carefully below--- notice how you can zoom right in on the individual cell and protein pathways. Overall, very informative for what is coming next week
http://www.brainshark.com/caliper/PHENOptics/zAyzRHN20z0z0
-------------------------------------------------------------
Excellent video above and many new toys from Perkin Elmer below that I want for Christmas this year...
Immuno-oncology has emerged as an exciting area of personalized medicine because of its tremendous potential to harness the powerful immune system to target and destroy cancer cells with few side effects, when targeted to the right tumor at the right time. Researchers are exploring the complex relationship between tumor cells and the immune system within the tumor microenvironment in order to discover new immuno-oncology and targets.
http://www.perkinelmer.com/category/cancer-immunotherapy-immunology
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
